PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the closing of its previously announced registered direct offering of an aggregate of 15,000,000 shares of its common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate of 15,000,000 shares of common stock, at a purchase price of $1.00 per share of common stoc ..read more

– Company creating de novo designed macrocycles with enhanced efficacy that precisely target disease biology The post Vilya Announces New Publication in Science Validating Foundational Approach to Design of Novel Chemically Diverse Macrocycles appeared first on Bio Tech Winners ..read more

CARBIOS feiert gemeinsam mit seinen Partnern die Grundsteinlegung für seine weltweit erste PET-Biorecycling-Anlage The post CARBIOS feiert gemeinsam mit seinen Partnern die Grundsteinlegung für seine weltweit erste PET-Biorecycling-Anlage appeared first on Bio Tech Winners ..read more

CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners The post CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners appeared first on Bio Tech Winners ..read more

CARBIOS pose la première pierre de son usine de biorecyclage du PET, une première mondiale, avec ses partenaires The post CARBIOS pose la première pierre de son usine de biorecyclage du PET, une première mondiale, avec ses partenaires appeared first on Bio Tech Winners ..read more

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC The post Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC appeared first on Bio Tech Winners ..read more

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced for the first time, quantitative data showing improvement in White Matter Z-scores measured from PET images taken at 3 months in nasal foralumab treated patients with non-active secondary progressive multiple sclerosis (na-SPMS). White Matter Z-scores are a statistical measure used in neuroimaging studies to assess the integrity or abnormalities in struc ..read more

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm The post Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic appeared first on Bio Tech Winners ..read more

Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial The post BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort appeared first on Bio Tech Winners ..read more

Boca Raton, Florida, April 25, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced today that it has entered into definitive agreements for the sale and purchase of 986,000 shares of its common stock and warrants to purchase up to an aggregate of 986,000 shares of its common stock at an offering price of $9.84 per share of common stock and accompanying warrant. The warrants include an acceleration clause upo ..read more